Search Result

Results for "

Tumor targeting peptide

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Peptide-Drug Conjugates (PDCs) (3) TNF Receptor (1) ADC Linker (1) Amino Acid Derivatives (2) Antifolate (2) Apoptosis (2) Biochemical Assay Reagents (45) Bombesin Receptor (1) Cadherin (1) Carbonic Anhydrase (1) Caspase (2) Complement System (2) CXCR (3) EBV (1) EGFR (3) Epigenetic Reader Domain (2) FAP (3) Fluorescent Dye (1) Folate Receptor (FR) (1) GSK-3 (1) HSP (1) Integrin (7) Interleukin Related (1) Liposome (28) Mitochondrial Metabolism (1) MMP (1) PARP (1) PD-1/PD-L1 (1) Protein Arginine Deiminase (1) Radionuclide-Drug Conjugates (RDCs) (20) Ser/Thr Kinase (1) Topoisomerase (1) Transmembrane Glycoprotein (1) TRP Channel (1) VEGFR (5) YAP (1)
By Research Areas:	Cancer (75) Cardiovascular Disease (1) Metabolic Disease (2)
Click Chemistry:	DBCO (1) Azide (2) Alkynes (4)
Oligonucleotides:	Pegylated Lipids (3)

109

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Click Chemistry

Oligonucleotides

Targets Recommended: Formyl Peptide Receptor (FPR) Connective Peptide Peptide-Drug Conjugates (PDCs) Natriuretic Peptide Receptor (NPR) TNF Receptor RXFP Receptor BRK CGRP Receptor Target Protein Ligand-Linker Conjugates Amyloid-β Ligands for Target Protein for PROTAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P10501A

FRα-targeting peptide C7 TFA	Antifolate	Cancer
FRα-targeting peptide C7 TFA is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 TFA can be used in the research of tumor diagnosis and treatment .

HY-P0122

iRGD peptide 5 Publications Verification c(CRGDKGPDC)	Integrin	Cancer
iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to αv-integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.

HY-P1828A

EGFRvIII peptide (PEPvIII) TFA	EGFR	Cancer
EGFRvIII peptide (PEPvIII) TFA is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide TFA represents a truly tumor-specific target for antitumor immunotherapy .

HY-P10501

FRα-targeting peptide C7	Antifolate	Cancer
FRα-targeting peptide C7 is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 can be used in the research of tumor diagnosis and treatment .

HY-P3707

Tumor targeted pro-apoptotic peptide	Apoptosis	Cancer
Tumor targeted pro-apoptotic peptide (CNGRC-GG-D(KLAKLAK)2) is an anti-tumor peptide. Tumor targeted pro-apoptotic peptide disrupts mitochondrial membranes and promotes apoptosis, showing anticancer activity in mice .

HY-P10709

CREKA peptide	Biochemical Assay Reagents	Cardiovascular Disease Cancer
CREKA peptide is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity .

HY-P1828

EGFRvIII peptide (PEPvIII)	EGFR	Cancer
EGFRvIII peptide (PEPvIII) is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide represents a truly tumor-specific target for antitumor immunotherapy .

HY-P10787

tLyP-1 peptide	Complement System	Cancer
tLyP-1 peptide is an NRP-1 targeting peptide with an IC₅₀ of 4 μM, and its amino acid sequence is CGNKRTR. tLyP-1 peptide specifically binds to NRP-1 to target tumor cells .

HY-P10679

GPLGLAGGWGERDGS	MMP	Cancer
GPLGLAGGWGERDGS is a peptide with MMP enzyme responsiveness and tumor targeting function, which can be used to monitor enzyme-guided nanoparticle assembly in tumors .

HY-P10792

HER2-targeted peptide H6F	EGFR	Cancer
HER2-targeted peptide H6F is a HER2 targeting peptide that binds to HER2 to target breast cancer cells, with the amino acid sequence YLFFVFER. The HER2-targeted peptide H6F can be conjugated with the bifunctional chelating agent hydrazinonicotinamide (HYNIC) for radiolabeling with 99mTc. Single-photon emission computed tomography (SPECT) imaging shows that the labeled HER2-targeted peptide H6F specifically accumulates in HER2-positive MDA-MBA-453 tumor-bearing mice models. The HER2-targeted peptide H6F can be used for tumor molecular imaging studies .

HY-172497

DSPE-PEG2000-CREKA	Liposome	Cancer
DSPE-PEG2000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG2000-CREKA can be used for drug delivery .

HY-172496

DSPE-PEG1000-CREKA	Liposome	Cancer
DSPE-PEG1000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG1000-CREKA can be used for drug delivery .

HY-172498

DSPE-PEG5000-CREKA	Liposome	Cancer
DSPE-PEG5000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG5000-CREKA can be used for drug delivery .

HY-172497A

DSPE-PEG3400-CREKA	Liposome	Cancer
DSPE-PEG3400-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG3400-CREKA can be used for drug delivery .

HY-P10786

LinTT1 peptide	Transmembrane Glycoprotein	Cancer
LinTT1 peptide is a tumor-penetrating peptide with the amino acid sequence AKRGARST. LinTT1 peptide targets peritoneal carcinoma (PC) by binding to the p32 (gC1qR) receptor. It can conjugate with iron oxide nanoworms (NWs) to form a nanocarrier. This nanocarrier is taken up by peritoneal carcinoma cells in vitro and enters the mitochondria; it also exhibits significant tumor targeting and penetration effects in mice. Moreover, LinTT1-functionalized nanocarriers, combined with the pro-apoptotic peptide [D(KLAKLAK)2], show significant tumor suppression in a mouse peritoneal tumor model. LinTT1 peptide holds promise as a delivery carrier for peritoneal cancer research .

HY-172491A

DSPE-PEG3400-ESBP	Liposome	Cancer
DSPE-PEG3400-ESBP is a PEG compound which composed of DSPE and a E-selectin-binding peptide (ESBP). As a tumor-targeting peptide, ESBP can specifically recognize and bind to receptors or markers on the surface of tumor cells .

HY-172491

DSPE-PEG2000-ESBP	Liposome	Cancer
DSPE-PEG2000-ESBP is a PEG compound which composed of DSPE and a E-selectin-binding peptide (ESBP). As a tumor-targeting peptide, ESBP can specifically recognize and bind to receptors or markers on the surface of tumor cells .

HY-172490

DSPE-PEG1000-ESBP	Liposome	Cancer
DSPE-PEG1000-ESBP is a PEG compound which composed of DSPE and a E-selectin-binding peptide (ESBP). As a tumor-targeting peptide, ESBP can specifically recognize and bind to receptors or markers on the surface of tumor cells .

HY-172492

DSPE-PEG5000-ESBP	Liposome	Cancer
DSPE-PEG5000-ESBP is a PEG compound which composed of DSPE and a E-selectin-binding peptide (ESBP). As a tumor-targeting peptide, ESBP can specifically recognize and bind to receptors or markers on the surface of tumor cells .

HY-P10983

LS10	Biochemical Assay Reagents	Cancer
LS10 can specifically bind to NG2 protein and is a functional ligand for targeted drug delivery to glioma. NG2 proteins are widely overexpressed in the glioma cells and restricted in normal tissue .

HY-172494A

DSPE-PEG3400-iRGD	Liposome Integrin	Cancer
DSPE-PEG3400-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG3400-iRGD can be used for drug delivery .

HY-172495

DSPE-PEG3000-iRGD	Liposome Integrin	Cancer
DSPE-PEG3000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG3000-iRGD can be used for drug delivery .

HY-172493

DSPE-PEG1000-iRGD	Liposome Integrin	Cancer
DSPE-PEG1000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG1000-iRGD can be used for drug delivery .

HY-172494

DSPE-PEG2000-iRGD	Liposome Integrin	Cancer
DSPE-PEG2000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG2000-iRGD can be used for drug delivery .

HY-P4091A

LSD acetate	Biochemical Assay Reagents	Cancer
LSD acetate is a peptide. LSD acetate can specifically recognize the lymphatics of C8161 melanoma, but it does not bind to the lymphatics of normal tissues or tumor blood vessels. When conjugated with a proapoptotic peptide, LSD acetate can reduce the number of tumor lymphatics. LSD acetate can be used in the research of targeted therapy and diagnosis of tumor lymphatics .

HY-P4091

LSD	Biochemical Assay Reagents	Cancer
LSD is a peptide. LSD can specifically recognize the lymphatics of C8161 melanoma, but it does not bind to the lymphatics of normal tissues or tumor blood vessels. When conjugated with a proapoptotic peptide, LSD can reduce the number of tumor lymphatics. LSD can be used in the research of targeted therapy and diagnosis of tumor lymphatics .

HY-P10705

KGFRWR	Biochemical Assay Reagents	Cancer
KGFRWR is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. KGFRWR can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity .

HY-138134

NOTP	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Others
NOTPis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NOTP can be used for conjugation of peptides and radionuclides.

HY-P10788

CK3 peptide	Complement System	Cancer
CK3 peptide is an NRP-1 targeting peptide with the amino acid sequence CLKADKAKC. The CK3 peptide specifically binds to NRP-1 to target breast cancer cells. Single-photon emission computed tomography (SPECT) and near-infrared fluorescence (NIRF) imaging show significant accumulation of CK3 peptide in xenograft tumors in nude mice. CK3 peptide can be used for molecular imaging studies of breast cancer.

HY-138269A

Barzuxetan hydrochloride CHX-A''-DTPA-NCS hydrochloride	Biochemical Assay Reagents	Others
Barzuxetan (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. Barzuxetan (hydrochloride) can be used for conjugation of peptides and radionuclides.

HY-134418A

NOTA trihydrochloride	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Others
NOTA (trihydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NOTA (trihydrochloride) can be used for conjugation of peptides and radionuclides.

HY-P10493

NY-ESO-1 (157-165) peptide	Amino Acid Derivatives	Cancer
NY-ESO-1 (157-165) peptide is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide is expressed in a variety of tumors and can be used as a target for tumor immunotherapy .

HY-P10493A

NY-ESO-1 (157-165) peptide TFA	Amino Acid Derivatives	Cancer
NY-ESO-1 (157-165) peptide (TFA) is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide (TFA) can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide (TFA) is expressed in a variety of tumors and can be used as a target for tumor immunotherapy .

HY-W088413

DOTA-amide	Biochemical Assay Reagents	Others
DOTA-amideis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-amide can be used for conjugation of peptides and radionuclides.

HY-W678394

DOTA-Thiol	Biochemical Assay Reagents	Others
DOTA-Thiolis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-Thiol can be used for conjugation of peptides and radionuclides.

HY-158067

Deferoxamine-DBCO DFO-DBCO	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Others
Deferoxamine-DBCOis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DFO derivative used for tumor pre-targeting. Deferoxamine-DBCO can be used for conjugation of peptides and radionuclides.

HY-W782078

Butyne-DOTA	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Others
Butyne-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA can be used for conjugation of peptides and radionuclides.

HY-P10894

mUNO	Epigenetic Reader Domain	Cancer
mUNO is a tumor-homing peptide (mUNO, sequence: "CSPGAK") that specifically binds to mouse CD206, targeting tumor-associated macrophages that express CD206/MRC1. mUNO can interact with human recombinant CD206 .

HY-158072

DOTAM-NHS-ester	Biochemical Assay Reagents	Others
DOTAM-NHS-esteris a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTAM-NHS-ester can be used for conjugation of peptides and radionuclides.

HY-W717743

DOTAM-mono-acid	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Others
DOTAM-mono-acidis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTAM-mono-acid can be used for conjugation of peptides and radionuclides.

HY-W717782

Bz-DTPA hydrochloride	Biochemical Assay Reagents	Others
Bz-DTPA (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. Bz-DTPA (hydrochloride) can be used for conjugation of peptides and radionuclides.

HY-W726767

DO2A	Biochemical Assay Reagents	Others
DO2Ais a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DO2A can be used for conjugation of peptides and radionuclides.

HY-P5520

GB-6	Bombesin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
GB-6 is a short linear peptide that targets the gastrin releasing peptide receptor (GRPR). GRPR is overexpressed in pancreatic cancer. Based on the tumor selectivity and tumor-specific accumulation properties of GB-6, GB-6 labeled with near infrared (NIR) fluorescent dyes or radionuclide netium-99m (99mTc) can be used as a high-contrast imaging probe. GB-6 has excellent in vivo stability, with tumor to pancreatic and intestinal fluorescence signal ratios of 5.2 and 6.3, respectively, in SW199 0 subcutaneous xenograft models. GB-6 can rapidly target tumors and accurately delineate tumor boundaries, which has broad application prospects .

HY-W087027A

Maleimide-NOTA TFA	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Others
Maleimide-NOTA (TFA)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. Maleimide-NOTA (TFA) can be used for conjugation of peptides and radionuclides.

HY-W250844A

DO3A trisodium	Biochemical Assay Reagents	Others
DO3A (trisodium)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DO3A (trisodium) can be used for conjugation of peptides and radionuclides.

HY-158077

(R)-tetraMe-Tetraxetan (R)-tetraMe-DOTA	Biochemical Assay Reagents	Others
(R)-tetraMe-Tetraxetanis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (R)-tetraMe-Tetraxetan can be used for conjugation of peptides and radionuclides.

HY-P10285

d-KLA Peptide D-(KLAKLAK)2	Mitochondrial Metabolism PARP Caspase	Cancer
d-KLA Peptide is a synthetic pro-apoptotic peptide. d-KLA Peptide can specifically target mitochondria and induce apoptosis by destroying the mitochondrial membrane. d-KLA Peptide activates biochemical pathways associated with apoptosis, including the activation of caspase family proteins and PARP (poly ADP ribose polymerase). d-KLA Peptide can be used to carry and deliver genes or small molecules to enhance anti-tumor effects .

HY-172272A

DSPE-PEG2000-A7R	Liposome VEGFR	Cancer
DSPE-PEG2000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .

HY-172272B

DSPE-PEG5000-A7R	Liposome VEGFR	Cancer
DSPE-PEG5000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .

HY-172272

DSPE-PEG1000-A7R	Liposome VEGFR	Cancer
DSPE-PEG1000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .

Cat. No.	Product Name

HY-L110

Cyclic Peptide Library

92 compounds

Cyclic peptides are polypeptide chains taking cyclic ring structure, which exhibit diverse biological activities, such as antibacterial activity, immunosuppressive activity and anti-tumor activity. Cyclic peptides, with the features of good binding affinity, target selectivity and low toxicity, show great success as therapeutics. Multiple cyclic peptides are currently in clinical use, for examples, gramicidin and tyrocidine with bactericidal activity, cyclosporin A with immunosuppressive activity, and vancomycin with antibacterial activity. Furthermore, cyclic peptides usually have the sufficient size and a balanced conformational flexibility/rigidity for binding to flat protein-protein interaction (PPI) interfaces, which have potential to develop PPI drugs.

MCE offers a unique collection of 92 cyclic peptides, all of which have good bioactivities. MCE Cyclic Peptide Library is a powerful tool for drug discovery and PPI inhibitor screening.

Cat. No.	Product Name	Type

HY-D2334

AlF-NOTA-c-d-VAP	Dyes
AlF-NOTA-c-d-VAP is a peptide positron emission tomography (PET) probe that used for targeted tumor imaging of GRP78. AlF-NOTA-c-d-VAP demonstrates high stability in vitro and in vivo .

HY-D2439

RGD-PEG-Cy3

Fluorescent Dyes/Probes

RGD-PEG-Cy3 is a fluorescent labeling reagent that combines Cy3 fluorescent dye, peptide (RGD) and polyethylene glycol (PEG). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Cy3 has an emission maximum around 562-570 nm. RGD is a peptide sequence (CRGDKGPDCiRGD) that binds to αvβ3 and αvβ5 integrin receptors on tumor neovasculogenesis to achieve specific tumor tissue targeting .

Cat. No.	Product Name	Type

HY-172497

DSPE-PEG2000-CREKA	Drug Delivery
DSPE-PEG2000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG2000-CREKA can be used for drug delivery .

HY-172496

DSPE-PEG1000-CREKA	Drug Delivery
DSPE-PEG1000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG1000-CREKA can be used for drug delivery .

HY-172498

DSPE-PEG5000-CREKA	Drug Delivery
DSPE-PEG5000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG5000-CREKA can be used for drug delivery .

HY-172497A

DSPE-PEG3400-CREKA	Drug Delivery
DSPE-PEG3400-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG3400-CREKA can be used for drug delivery .

HY-172491A

DSPE-PEG3400-ESBP	Drug Delivery
DSPE-PEG3400-ESBP is a PEG compound which composed of DSPE and a E-selectin-binding peptide (ESBP). As a tumor-targeting peptide, ESBP can specifically recognize and bind to receptors or markers on the surface of tumor cells .

HY-172491

DSPE-PEG2000-ESBP	Drug Delivery
DSPE-PEG2000-ESBP is a PEG compound which composed of DSPE and a E-selectin-binding peptide (ESBP). As a tumor-targeting peptide, ESBP can specifically recognize and bind to receptors or markers on the surface of tumor cells .

HY-172490

DSPE-PEG1000-ESBP	Drug Delivery
DSPE-PEG1000-ESBP is a PEG compound which composed of DSPE and a E-selectin-binding peptide (ESBP). As a tumor-targeting peptide, ESBP can specifically recognize and bind to receptors or markers on the surface of tumor cells .

HY-172492

DSPE-PEG5000-ESBP	Drug Delivery
DSPE-PEG5000-ESBP is a PEG compound which composed of DSPE and a E-selectin-binding peptide (ESBP). As a tumor-targeting peptide, ESBP can specifically recognize and bind to receptors or markers on the surface of tumor cells .

HY-172494A

DSPE-PEG3400-iRGD	Drug Delivery
DSPE-PEG3400-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG3400-iRGD can be used for drug delivery .

HY-172495

DSPE-PEG3000-iRGD	Drug Delivery
DSPE-PEG3000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG3000-iRGD can be used for drug delivery .

HY-172493

DSPE-PEG1000-iRGD	Drug Delivery
DSPE-PEG1000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG1000-iRGD can be used for drug delivery .

HY-172494

DSPE-PEG2000-iRGD	Drug Delivery
DSPE-PEG2000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG2000-iRGD can be used for drug delivery .

HY-138134

NOTP	Chelators
NOTPis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NOTP can be used for conjugation of peptides and radionuclides.

HY-138269A

Barzuxetan hydrochloride CHX-A''-DTPA-NCS hydrochloride	Chelators
Barzuxetan (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. Barzuxetan (hydrochloride) can be used for conjugation of peptides and radionuclides.

HY-134418A

NOTA trihydrochloride	Chelators
NOTA (trihydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NOTA (trihydrochloride) can be used for conjugation of peptides and radionuclides.

HY-W088413

DOTA-amide	Chelators
DOTA-amideis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-amide can be used for conjugation of peptides and radionuclides.

HY-W678394

DOTA-Thiol	Chelators
DOTA-Thiolis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-Thiol can be used for conjugation of peptides and radionuclides.

HY-158067

Deferoxamine-DBCO DFO-DBCO	Chelators
Deferoxamine-DBCOis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DFO derivative used for tumor pre-targeting. Deferoxamine-DBCO can be used for conjugation of peptides and radionuclides.

HY-W782078

Butyne-DOTA	Chelators
Butyne-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA can be used for conjugation of peptides and radionuclides.

HY-158072

DOTAM-NHS-ester	Chelators
DOTAM-NHS-esteris a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTAM-NHS-ester can be used for conjugation of peptides and radionuclides.

HY-W717743

DOTAM-mono-acid	Chelators
DOTAM-mono-acidis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTAM-mono-acid can be used for conjugation of peptides and radionuclides.

HY-W717782

Bz-DTPA hydrochloride	Chelators
Bz-DTPA (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. Bz-DTPA (hydrochloride) can be used for conjugation of peptides and radionuclides.

HY-W726767

DO2A	Chelators
DO2Ais a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DO2A can be used for conjugation of peptides and radionuclides.

HY-W087027A

Maleimide-NOTA TFA	Chelators
Maleimide-NOTA (TFA)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. Maleimide-NOTA (TFA) can be used for conjugation of peptides and radionuclides.

HY-W250844A

DO3A trisodium	Chelators
DO3A (trisodium)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DO3A (trisodium) can be used for conjugation of peptides and radionuclides.

HY-158077

(R)-tetraMe-Tetraxetan (R)-tetraMe-DOTA	Chelators
(R)-tetraMe-Tetraxetanis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (R)-tetraMe-Tetraxetan can be used for conjugation of peptides and radionuclides.

HY-172272A

DSPE-PEG2000-A7R	Drug Delivery
DSPE-PEG2000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .

HY-172272B

DSPE-PEG5000-A7R	Drug Delivery
DSPE-PEG5000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .

HY-172272

DSPE-PEG1000-A7R	Drug Delivery
DSPE-PEG1000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .

HY-172272C

DSPE-PEG3400-A7R	Drug Delivery
DSPE-PEG3400-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .

HY-172473

DSPE-PEG2000-NGR	Drug Delivery
DSPE-PEG2000-NGR is a PEG compound which composed of DSPE and an Asn-Gly-Arg (NGR) peptide. NGR peptide can target tumor vascular antigen CD13. DSPE-PEG2000-NGR can be used for drug delivery .

HY-172473A

DSPE-PEG3400-NGR	Drug Delivery
DSPE-PEG34000-NGR is a PEG compound which composed of DSPE and an Asn-Gly-Arg (NGR) peptide. NGR peptide can target tumor vascular antigen CD13. DSPE-PEG3400-NGR can be used for drug delivery .

HY-172474

DSPE-PEG5000-NGR	Drug Delivery
DSPE-PEG5000-NGR is a PEG compound which composed of DSPE and an Asn-Gly-Arg (NGR) peptide. NGR peptide can target tumor vascular antigen CD13. DSPE-PEG5000-NGR can be used for drug delivery .

HY-172472

DSPE-PEG1000-NGR	Drug Delivery
DSPE-PEG1000-NGR is a PEG compound which composed of DSPE and an Asn-Gly-Arg (NGR) peptide. NGR peptide can target tumor vascular antigen CD13. DSPE-PEG1000-NGR can be used for drug delivery .

HY-W539916

Azido-mono-amide-DOTA	Chelators
Azido-mono-amide-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Azido-mono-amide-DOTA can be used for conjugation of peptides and radionuclides.

HY-W717779

4-Aminobutyl-DOTA	Chelators
4-Aminobutyl-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. 4-Aminobutyl-DOTA can be used for conjugation of peptides and radionuclides.

HY-128890A

DOTA-NHS-ester hexafluorophosphate TFA	Chelators
DOTA-NHS-ester (hexafluorophosphate TFA)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-NHS-ester (hexafluorophosphate TFA) can be used for conjugation of peptides and radionuclides.

HY-A0074

DTPA-tetra (t-Bu ester) tetra-tBu-DTPA	Chelators
DTPA-tetra (t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. DTPA-tetra (t-Bu ester) can be used for conjugation of peptides and radionuclides.

HY-W782087A

p-SCN-Bn-PCTA hydrochloride	Chelators
p-SCN-Bn-PCTA (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. p-SCN-Bn-PCTA (hydrochloride) can be used for conjugation of peptides and radionuclides.

HY-W717781A

p-NH₂-Bn-DTPA hydrochloride	Chelators
p-NH?-Bn-DTPA (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. p-NH?-Bn-DTPA (hydrochloride) can be used for conjugation of peptides and radionuclides.

HY-W782088A

p-NH₂-Bn-PCTA hydrochloride	Chelators
p-NH?-Bn-PCTA (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. p-NH?-Bn-PCTA (hydrochloride) can be used for conjugation of peptides and radionuclides.

HY-W802013

DOTA-4AMP	Chelators
DOTA-4AMPis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-4AMP can be used for conjugation of peptides and radionuclides.

HY-158068

Maleimido-mono-amide-DTPA TFA	Chelators
Maleimido-mono-amide-DTPA (TFA)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. Maleimido-mono-amide-DTPA (TFA) can be used for conjugation of peptides and radionuclides.

HY-W749627

NO2A-Butyne	Chelators
NO2A-Butyneis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Butyne can be used for conjugation of peptides and radionuclides.

HY-W451440

Butyne-DOTA-tris(t-butyl ester)	Chelators
Butyne-DOTA-tris(t-butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA-tris(t-butyl ester) can be used for conjugation of peptides and radionuclides.

HY-131673A

(S)-p-SCN-Bn-TCMC hydrochloride	Chelators
(S)-p-SCN-Bn-TCMC (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (S)-p-SCN-Bn-TCMC (hydrochloride) can be used for conjugation of peptides and radionuclides.

HY-W717800A

NO2A-Azide trihydrochloride	Chelators
NO2A-Azide (trihydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Azide (trihydrochloride) can be used for conjugation of peptides and radionuclides.

HY-W717833

NO2A-(t-Bu ester)	Chelators
NO2A-(t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-(t-Bu ester) can be used for conjugation of peptides and radionuclides.

HY-W782075

p-NO2-Bn-DOTA	Chelators
p-NO2-Bn-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NO2-Bn-DOTA can be used for conjugation of peptides and radionuclides.

HY-48876

p-NH2-Bn-DOTA	Chelators
p-NH2-Bn-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NH2-Bn-DOTA can be used for conjugation of peptides and radionuclides.

Cat. No.	Product Name	Target	Research Area

HY-P10501A

FRα-targeting peptide C7 TFA	Antifolate	Cancer
FRα-targeting peptide C7 TFA is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 TFA can be used in the research of tumor diagnosis and treatment .

HY-P0122

iRGD peptide 5 Publications Verification c(CRGDKGPDC)	Integrin	Cancer
iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to αv-integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.

HY-P10501

FRα-targeting peptide C7	Antifolate	Cancer
FRα-targeting peptide C7 is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 can be used in the research of tumor diagnosis and treatment .

HY-P10449

M2 Peptide	Peptides	Cancer
M2 Peptide is a peptide targeting M2-like tumor-associated macrophages (TAMs). M2 Peptide is used to carry drugs or small interfering RNA (siRNA) to promote the repolarization of M2-like macrophages to M1-like macrophages, thereby altering the immunosuppressive state in the tumor microenvironment and enhancing the anti-tumor immune response. M2 Peptide can be used to study the effect of macrophage polarization and how this polarization change affects tumor growth and metastasis .

HY-P3707

Tumor targeted pro-apoptotic peptide	Apoptosis	Cancer
Tumor targeted pro-apoptotic peptide (CNGRC-GG-D(KLAKLAK)2) is an anti-tumor peptide. Tumor targeted pro-apoptotic peptide disrupts mitochondrial membranes and promotes apoptosis, showing anticancer activity in mice .

HY-P10709

CREKA peptide	Biochemical Assay Reagents	Cardiovascular Disease Cancer
CREKA peptide is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity .

HY-P4903

RGD-targeted Proapoptotic Peptide	Peptides	Cancer
RGD-targeted Proapoptotic Peptide is a peptide. The C-terminal RGD-4C peptide (ACDCRGDCFC) binds preferentially to integrins at sites of tumor angiogenesis.

HY-P1828

EGFRvIII peptide (PEPvIII)	EGFR	Cancer
EGFRvIII peptide (PEPvIII) is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide represents a truly tumor-specific target for antitumor immunotherapy .

HY-P10787

tLyP-1 peptide	Complement System	Cancer
tLyP-1 peptide is an NRP-1 targeting peptide with an IC₅₀ of 4 μM, and its amino acid sequence is CGNKRTR. tLyP-1 peptide specifically binds to NRP-1 to target tumor cells .

HY-P10679

GPLGLAGGWGERDGS	MMP	Cancer
GPLGLAGGWGERDGS is a peptide with MMP enzyme responsiveness and tumor targeting function, which can be used to monitor enzyme-guided nanoparticle assembly in tumors .

HY-P4116

pH-Low Insertion Peptide pHLIP	Peptides	Metabolic Disease Cancer
pH-Low Insertion Peptide (pHLIP) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide successfully modify polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide-based targeting of cancer presents an opportunity to monitor metabolic changes, and to selectively deliver imaging and therapeutic agents to tumors .

HY-P1828A

EGFRvIII peptide (PEPvIII) TFA	EGFR	Cancer
EGFRvIII peptide (PEPvIII) TFA is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide TFA represents a truly tumor-specific target for antitumor immunotherapy .

HY-P10792

HER2-targeted peptide H6F	EGFR	Cancer
HER2-targeted peptide H6F is a HER2 targeting peptide that binds to HER2 to target breast cancer cells, with the amino acid sequence YLFFVFER. The HER2-targeted peptide H6F can be conjugated with the bifunctional chelating agent hydrazinonicotinamide (HYNIC) for radiolabeling with 99mTc. Single-photon emission computed tomography (SPECT) imaging shows that the labeled HER2-targeted peptide H6F specifically accumulates in HER2-positive MDA-MBA-453 tumor-bearing mice models. The HER2-targeted peptide H6F can be used for tumor molecular imaging studies .

HY-P10786

LinTT1 peptide	Transmembrane Glycoprotein	Cancer
LinTT1 peptide is a tumor-penetrating peptide with the amino acid sequence AKRGARST. LinTT1 peptide targets peritoneal carcinoma (PC) by binding to the p32 (gC1qR) receptor. It can conjugate with iron oxide nanoworms (NWs) to form a nanocarrier. This nanocarrier is taken up by peritoneal carcinoma cells in vitro and enters the mitochondria; it also exhibits significant tumor targeting and penetration effects in mice. Moreover, LinTT1-functionalized nanocarriers, combined with the pro-apoptotic peptide [D(KLAKLAK)2], show significant tumor suppression in a mouse peritoneal tumor model. LinTT1 peptide holds promise as a delivery carrier for peritoneal cancer research .

HY-P10983

LS10	Biochemical Assay Reagents	Cancer
LS10 can specifically bind to NG2 protein and is a functional ligand for targeted drug delivery to glioma. NG2 proteins are widely overexpressed in the glioma cells and restricted in normal tissue .

HY-P10989

NG2 binding peptide	Peptides	Cancer
NG2 binding peptide is a short peptide that specifically recognizes NG2 proteoglycan and can be obtained by phage screening technology. NG2 binding peptide interacts with NG2 binding sites to achieve precise targeting of tumor angiogenesis in vitro and in vivo. NG2 binding peptide exhibits significant homing ability in wild-type tumor-bearing mice, but has no localization effect in NG2 knockout mice. Due to the tissue specificity of NG2 expression, NG2 binding peptide can be used in scenarios such as tumor targeted therapy, drug delivery, and molecular imaging diagnosis .

HY-P4116A

pH-Low Insertion Peptide TFA pHLIP TFA	Peptides	Metabolic Disease Cancer
pH-Low Insertion Peptide TFA (pHLIP TFA) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide TFA targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide TFA successfully modifys polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide TFA -based targeting of cancer presents an opportunity to monitor metabolic changes and to selectively deliver imaging and therapeutic agents to tumors .

HY-P4091A

LSD acetate	Biochemical Assay Reagents	Cancer
LSD acetate is a peptide. LSD acetate can specifically recognize the lymphatics of C8161 melanoma, but it does not bind to the lymphatics of normal tissues or tumor blood vessels. When conjugated with a proapoptotic peptide, LSD acetate can reduce the number of tumor lymphatics. LSD acetate can be used in the research of targeted therapy and diagnosis of tumor lymphatics .

HY-P4091

LSD	Biochemical Assay Reagents	Cancer
LSD is a peptide. LSD can specifically recognize the lymphatics of C8161 melanoma, but it does not bind to the lymphatics of normal tissues or tumor blood vessels. When conjugated with a proapoptotic peptide, LSD can reduce the number of tumor lymphatics. LSD can be used in the research of targeted therapy and diagnosis of tumor lymphatics .

HY-P10705

KGFRWR	Biochemical Assay Reagents	Cancer
KGFRWR is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. KGFRWR can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity .

HY-P10788

CK3 peptide	Complement System	Cancer
CK3 peptide is an NRP-1 targeting peptide with the amino acid sequence CLKADKAKC. The CK3 peptide specifically binds to NRP-1 to target breast cancer cells. Single-photon emission computed tomography (SPECT) and near-infrared fluorescence (NIRF) imaging show significant accumulation of CK3 peptide in xenograft tumors in nude mice. CK3 peptide can be used for molecular imaging studies of breast cancer.

HY-P10493

NY-ESO-1 (157-165) peptide	Amino Acid Derivatives	Cancer
NY-ESO-1 (157-165) peptide is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide is expressed in a variety of tumors and can be used as a target for tumor immunotherapy .

HY-P10493A

NY-ESO-1 (157-165) peptide TFA	Amino Acid Derivatives	Cancer
NY-ESO-1 (157-165) peptide (TFA) is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide (TFA) can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide (TFA) is expressed in a variety of tumors and can be used as a target for tumor immunotherapy .

HY-P10894

mUNO	Epigenetic Reader Domain	Cancer
mUNO is a tumor-homing peptide (mUNO, sequence: "CSPGAK") that specifically binds to mouse CD206, targeting tumor-associated macrophages that express CD206/MRC1. mUNO can interact with human recombinant CD206 .

HY-P5520

GB-6	Bombesin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
GB-6 is a short linear peptide that targets the gastrin releasing peptide receptor (GRPR). GRPR is overexpressed in pancreatic cancer. Based on the tumor selectivity and tumor-specific accumulation properties of GB-6, GB-6 labeled with near infrared (NIR) fluorescent dyes or radionuclide netium-99m (99mTc) can be used as a high-contrast imaging probe. GB-6 has excellent in vivo stability, with tumor to pancreatic and intestinal fluorescence signal ratios of 5.2 and 6.3, respectively, in SW199 0 subcutaneous xenograft models. GB-6 can rapidly target tumors and accurately delineate tumor boundaries, which has broad application prospects .

HY-P10285

d-KLA Peptide D-(KLAKLAK)2	Mitochondrial Metabolism PARP Caspase	Cancer
d-KLA Peptide is a synthetic pro-apoptotic peptide. d-KLA Peptide can specifically target mitochondria and induce apoptosis by destroying the mitochondrial membrane. d-KLA Peptide activates biochemical pathways associated with apoptosis, including the activation of caspase family proteins and PARP (poly ADP ribose polymerase). d-KLA Peptide can be used to carry and deliver genes or small molecules to enhance anti-tumor effects .

HY-P10742

CBX-12	Peptide-Drug Conjugates (PDCs) Topoisomerase	Cancer
CBX-12 is a PDC (peptide drug conjugate) that targets tumors in an antigen-independent manner and exhibits antitumor activity. CBX-12 consists of a pH-sensitive peptide (pHLIP), a self-immolating linker, and a topoisomerase 1 (TOP1) inhibitor Exatecan (HY-13631) .

HY-P10131

3BP-3940	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
3BP-3940 is a highly potent and selective peptide inhibitor of FAP that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. 3BP-3940 can be labeled with radionuclides (such as Ga-68) for precise tumor imaging or Lu-177 for the development of targeted anticancer technologies. 3BP-3940 accumulates in tumor lesions and can be used to diagnose and inhibit various solid cancers and CAFs-related diseases .

HY-113003

H-γ-Glu-Gln-OH γ-Glutamylglutamine; γ-Glu-Gln	Peptides	Others Cancer
H-γ-Glu-Gln-OH is a hydrophilic peptide and can be conjugated to drugs. The carrier composed of H-γ-Glu-Gln-OH has the characteristics of high water solubility and drug-loading capacity, good biocompatibility, low toxicity, improved tumor targeting ability, and anti-tumor efficacy .

HY-P3441

3BP-4089	FAP	Cancer
3BP-4089 is a highly potent fibroblast activation protein (FAP)-targeting peptide for theranostics. 3BP-4089 is often coupled with radionuclides for tumor diagnosis and research .

HY-P3441A

3BP-4089 TFA	FAP	Cancer
3BP-4089 TFA is a highly potent fibroblast activation protein (FAP)-targeting peptide for theranostics. 3BP-4089 TFA is often coupled with radionuclides for tumor diagnosis and research .

HY-P3440

WL12	Radionuclide-Drug Conjugates (RDCs) PD-1/PD-L1	Cancer
WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression .

HY-P10761

DPI-4452	Radionuclide-Drug Conjugates (RDCs) Carbonic Anhydrase	Cancer
DPI-4452 is a *CAIX*-targeting cyclic peptide with a DOTA cage, and can be chelated with radionuclide for CAIX-expressing tumor PET-CT imaging and study. DPI-4452 specifically and selectively binds CAIX without interaction with an in vitro off-target receptor panel of 55 targets (IC₅₀ for recombinant hCAIX: 130 nM). Radiolabeled DPI-4452 inhibits tumor growth in HT-29 and SK-RC-52 xenograft mouse models . DPI-4452 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P11011

Peptide R54 Pep R54; CXCR4 antagonist peptide 19	CXCR	Cancer
Peptide R54 (Pep R54; CXCR4 antagonist peptide 19) is an antagonistic peptide targeting CXCR4 with significant anticancer activity. Peptide R54 inhibits CXCR4-dependent cell migration, epithelial-mesenchymal transition, and lung metastasis development, with better serum stability and higher CXCR4 affinity than the lead compound (IC₅₀=20 nM). Peptide R54 synergizes with anti-PD-1 therapy to exert anti-tumor activity in vivo, enhances granzyme activity, and reduces infiltration of Foxp3 cells. Peptide R54 can be used in the study of colon cancer, ovarian cancer, and melanoma .

HY-P10947

MACTIDE-V	Epigenetic Reader Domain YAP	Cancer
MACTIDE-V is an orally active and selective peptide-drug conjugate targeting CD206. MACTIDE-V delivers Verteporfin (HY-B0146) to CD206 ⁺ tumor-associated macrophages (TAM) to inhibit the YAP/TAZ signaling pathway, prompting YAP exclusion from the nucleus, inducing TAM polarization toward an anti-tumoral phenotype with enhanced phagocytosis and antigen presentation, and boosting T cell infiltration and NK cell activity. MACTIDE-V suppresses primary tumor growth and lung metastasis in triple-negative breast cancer (TNBC) mouse models .

HY-P10772

L2P4	Peptide-Drug Conjugates (PDCs) EBV	Cancer
L2P4 is a peptide-based and EBNA1 targeting fluorescent probe, which inhibits the EBNA1 homodimer formation and selectively inhibits EBV+ tumor growth. L2P4 exhibits cytotoxicity in EBV-positive C666-1 cell with LC₅₀ of 46.4 μM .

HY-P10934

LXY3 LXY2	Integrin	Cancer
LXY3 (LXY2) is a VLA-3-blocking peptide that inhibits the interaction between integrin α3β1 (VLA-3) on neutrophil surfaces and laminin in the basement membrane, thereby preventing neutrophil migration across the tumor vascular basement membrane barrier. LXY3 is used to block neutrophil-mediated nanoparticle release from perivascular pools into the tumor interstitium. LXY3 is commonly employed for targeted imaging of breast cancer .

HY-P10444

DOTA Conjugated JM#21 derivative 7	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10417

RTDLDSLRTYTL	Integrin	Others Cancer
RTDLDSLRTYTL is an Alpha (v) beta (6) integrin (avb6) inhibitor with high affinity and specificity. RTDLDSLRTYTL binds to avb6 integrin, a peptide sequence that activates cytotoxicity and cytokine production in T cells, such as interferon-gamma. RTDLDSLRTYTL is designed through a chimeric T cell antigen receptor (CAR) so that T cells can be redirected to specifically recognize and attack tumor cells. RTDLDSLRTYTL can be used in the research of cancer immunotherapy and targeted drug development .

HY-P10762

CBP-1008 LDC 10B	Peptide-Drug Conjugates (PDCs) Folate Receptor (FR) TRP Channel	Cancer
CBP-1008 is a dual-ligand *peptide*-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. CBP-1008 binds to FRα with high affinity and TRPV6 with low affinity. CBP-1008 has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .

HY-P10971

Nef-M1	CXCR Apoptosis VEGFR GSK-3 Cadherin Caspase	Cancer
Nef-M1 (Nef-Motif-1) is an antagonist peptide targeting CXCR4 and an apoptosis inducer derived from a myristoylated protein encoded by the nef gene in HIV. Nef-M1 inhibits tumor angiogenesis and epithelial-mesenchymal transition (EMT). Nef-M1 activates the apoptosis pathway by increasing the level of caspase-3 in cancer cells. Nef-M1 simultaneously inhibits VEGF-A, p-GSK-3β and vimentin, and enhances E-cadherin, thereby inhibiting angiogenesis and EMT processes. Nef-M1 can be used in the study of colorectal cancer and breast cancer .

Cat. No.	Product Name	Target	Research Area

HY-P99339

Tebentafusp IMCgp100	Interleukin Related TNF Receptor	Cancer
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor* cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells .

Cat. No.	Product Name		Classification

HY-158067

Deferoxamine-DBCO DFO-DBCO		DBCO
Deferoxamine-DBCOis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DFO derivative used for tumor pre-targeting. Deferoxamine-DBCO can be used for conjugation of peptides and radionuclides.

HY-W782078

Butyne-DOTA		Alkynes
Butyne-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA can be used for conjugation of peptides and radionuclides.

HY-W539916

Azido-mono-amide-DOTA		Azide
Azido-mono-amide-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Azido-mono-amide-DOTA can be used for conjugation of peptides and radionuclides.

HY-W749627

NO2A-Butyne		Alkynes
NO2A-Butyneis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Butyne can be used for conjugation of peptides and radionuclides.

HY-W451440

Butyne-DOTA-tris(t-butyl ester)		Alkynes
Butyne-DOTA-tris(t-butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA-tris(t-butyl ester) can be used for conjugation of peptides and radionuclides.

HY-W717800A

NO2A-Azide trihydrochloride		Azide
NO2A-Azide (trihydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Azide (trihydrochloride) can be used for conjugation of peptides and radionuclides.

HY-W749614

NO2A-Butyne-bis(t-Butyl ester)		Alkynes
NO2A-Butyne-bis(t-Butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Butyne-bis(t-Butyl ester) can be used for conjugation of peptides and radionuclides.

Cat. No.	Product Name		Classification

HY-172495

DSPE-PEG3000-iRGD		Pegylated Lipids
DSPE-PEG3000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG3000-iRGD can be used for drug delivery .

HY-172493

DSPE-PEG1000-iRGD		Pegylated Lipids
DSPE-PEG1000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG1000-iRGD can be used for drug delivery .

HY-172494

DSPE-PEG2000-iRGD		Pegylated Lipids
DSPE-PEG2000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG2000-iRGD can be used for drug delivery .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Tumor targeting peptide

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Click Chemistry

Oligonucleotides

Natural
Products